B P Sharma1, Amit Kumar1, Saubhik Das1, Shambhu Prasad1. 1. Dept of Orthopaedics, Central Institute of Orthopaedics (CIO), Vardhman Mahavir Medical College and Safdarjung Hospital, Delhi, India.
Abstract
BACKGROUND: Tuberculosis is one of the common disease of Indian subcontinent. India has the highest TB burden, accounting for one fifth of the global incidence. Previous studies have shown positive response of immunomodulation in patients of ostearticular tuberculosis We did this prospective study to assess the role of immunomodulation in the cases of osteoarticular tuberculosis who were not responding to anti tubercular therapy. MATERIALS AND METHOD: This study was conducted in our institute. New patients presenting to OPD who were diagnosed with tuberculosis with no previous history of taking anti tubercular treatment were enrolled. Total of 109 patients were diagnosed clinicoradiologically. Four patients, where diagnosis was not confirmed, histopathological examination of tissue was done and the diagnosis was confirmed as tubercular in origin. Newly diagnosed patients were put on anti tubercular therapy(ATT) after documenting there blood parameters (complete hemogram,ESR, serum proteins, CD4 & CD8 counts). After 3 months patients were re-evaluated and favourably responding patients were labelled group A. Those who did not respond to therapy were put on immunomodulation along with continuation of ATT. These were designated as group B and blood parameters were compared with pre immunomodulation values. RESULTS: Out of total 109 patients registered, 73 patients were enlisted in group A, while 30 patients were found to be non-responsive to ATT and were included in non-responder group B (six lost to follow up). In group B the blood parameters after one month of completion of immunomodulation showed statistically significant increase in CD4 & CD8 counts (p = 0.04). Mean CD4 count increased from 488/mm3 to 747/mm3 while CD8 count showed increment from 494/mm3 to 617/mm3. Mean haemoglobin values increased along with decrease in ESR and total leucocyte count. In group A mean CD4 and CD8 counts increased with ATT though the results were not significant statistically. CONCLUSION: Treatment: of tuberculosis has been a great success after introduction of chemotherapy specifically targeting Mycobacterium tuberculosis. In this study relationship between the increase in the peripheral T-cell count and a favourable clinical outcome was further associated with concomitant increase in the haemoglobin level as well as by a decrease in the ESR, total leucocyte count. In our study immunomodulation has shown a good promise to be of adjunctive use in patients on ATT with non-responsiveness.
BACKGROUND: Tuberculosis is one of the common disease of Indian subcontinent. India has the highest TB burden, accounting for one fifth of the global incidence. Previous studies have shown positive response of immunomodulation in patients of ostearticular tuberculosis We did this prospective study to assess the role of immunomodulation in the cases of osteoarticular tuberculosis who were not responding to anti tubercular therapy. MATERIALS AND METHOD: This study was conducted in our institute. New patients presenting to OPD who were diagnosed with tuberculosis with no previous history of taking anti tubercular treatment were enrolled. Total of 109 patients were diagnosed clinicoradiologically. Four patients, where diagnosis was not confirmed, histopathological examination of tissue was done and the diagnosis was confirmed as tubercular in origin. Newly diagnosed patients were put on anti tubercular therapy(ATT) after documenting there blood parameters (complete hemogram,ESR, serum proteins, CD4 & CD8 counts). After 3 months patients were re-evaluated and favourably responding patients were labelled group A. Those who did not respond to therapy were put on immunomodulation along with continuation of ATT. These were designated as group B and blood parameters were compared with pre immunomodulation values. RESULTS: Out of total 109 patients registered, 73 patients were enlisted in group A, while 30 patients were found to be non-responsive to ATT and were included in non-responder group B (six lost to follow up). In group B the blood parameters after one month of completion of immunomodulation showed statistically significant increase in CD4 & CD8 counts (p = 0.04). Mean CD4 count increased from 488/mm3 to 747/mm3 while CD8 count showed increment from 494/mm3 to 617/mm3. Mean haemoglobin values increased along with decrease in ESR and total leucocyte count. In group A mean CD4 and CD8 counts increased with ATT though the results were not significant statistically. CONCLUSION: Treatment: of tuberculosis has been a great success after introduction of chemotherapy specifically targeting Mycobacterium tuberculosis. In this study relationship between the increase in the peripheral T-cell count and a favourable clinical outcome was further associated with concomitant increase in the haemoglobin level as well as by a decrease in the ESR, total leucocyte count. In our study immunomodulation has shown a good promise to be of adjunctive use in patients on ATT with non-responsiveness.
Authors: Frank Stegelmann; Max Bastian; Kay Swoboda; Rauf Bhat; Viviane Kiessler; Alan M Krensky; Martin Roellinghoff; Robert L Modlin; Steffen Stenger Journal: J Immunol Date: 2005-12-01 Impact factor: 5.422
Authors: Dennis Montoya; Megan S Inkeles; Phillip T Liu; Susan Realegeno; Rosane M B Teles; Poorva Vaidya; Marcos A Munoz; Mirjam Schenk; William R Swindell; Rene Chun; Kathryn Zavala; Martin Hewison; John S Adams; Steve Horvath; Matteo Pellegrini; Barry R Bloom; Robert L Modlin Journal: Sci Transl Med Date: 2014-08-20 Impact factor: 17.956
Authors: Georgiana M Klug-Micu; Steffen Stenger; Andrea Sommer; Philip T Liu; Stephan R Krutzik; Robert L Modlin; Mario Fabri Journal: Immunology Date: 2013-05 Impact factor: 7.397
Authors: A M Jackson; A B Alexandroff; R W Kelly; A Skibinska; K Esuvaranathan; S Prescott; G D Chisholm; K James Journal: Clin Exp Immunol Date: 1995-03 Impact factor: 4.330
Authors: Crystal Y Chen; Dan Huang; Richard C Wang; Ling Shen; Gucheng Zeng; Shuyun Yao; Yun Shen; Lisa Halliday; Jeff Fortman; Milton McAllister; Jim Estep; Robert Hunt; Daphne Vasconcelos; George Du; Steven A Porcelli; Michelle H Larsen; William R Jacobs; Barton F Haynes; Norman L Letvin; Zheng W Chen Journal: PLoS Pathog Date: 2009-04-17 Impact factor: 6.823